AR049353A1 - Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. - Google Patents
Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion.Info
- Publication number
- AR049353A1 AR049353A1 ARP050102433A ARP050102433A AR049353A1 AR 049353 A1 AR049353 A1 AR 049353A1 AR P050102433 A ARP050102433 A AR P050102433A AR P050102433 A ARP050102433 A AR P050102433A AR 049353 A1 AR049353 A1 AR 049353A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- disease
- alkyl
- hydroxy
- Prior art date
Links
- -1 CARBOXYL Chemical class 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 201000006549 dyspepsia Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 208000029493 gastroesophageal disease Diseases 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 125000005545 phthalimidyl group Chemical group 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones que contienen tales compuestos y el uso de tales compuestos en el tratamiento de una afeccion mediada por la actividad del receptor 5-HT4 tal como, pero sin limitacion a, enfermedad de reflujo gastroesofágico, enfermedad gastrointestinal, trastorno de motilidad gástrica, dispepsia no ulcerosa, dispepsia funcional, síndrome de intestino irritable (IBS), estrenimiento, dispepsia, esofagitis, enfermedad gastroesofágica, náuseas, enfermedad del sistema nervioso central, enfermedad de Alzheimer, trastorno cognitivo, emesis, migrana, enfermedad neurologica, dolor, trastornos cardiovasculares, tales como insuficiencia cardíaca y arritmia cardíaca, diabetes y síndrome de apnea. Reivindiacion 1: Un compuesto de formula (1) o una sal o solvato farmacéuticamente aceptable del mismo, en la que: A es un grupo alquileno C1-4, estando dicho grupo alquileno no substituido o substituido con 1 a 4 substituyentes seleccionados independientemente entre el grupo constituido por un átomo de halogeno, un grupo alquilo C1-4, un grupo hidroxi, -alquilo C1-4 y un grupo alxcoxi-alquilo C2-6, en el que dos sustituyentes cualquiera no halogeno se pueden tomar junto con los átomos de C a los que están unidos para formar un anillo de 3 a 6 miembros que opcionalmente contiene al menos un heteroátomo seleccionado entre N, O, y S; R1 es un grupo isopropilo o un grupo ciclopentilo; R2 es un átomo de H, un átomo de halogeno o un grupo hidroxi; R3 es un grupo carboxi, un grupo tetrazolilo, un grupo 5-oxo-1,2,4-oxadiazol-3-ilo o un grupo 5-oxo-1,2,4-tiadiazol-3-ilo; y m es un numero entero 1 o 2. Reivindicacion 11: Un compuesto de formula (2) o una sal del mismo, en la que: R2 es un átomo e H, un grupo hidroxi o un átomo de halogeno; R6 es un átomo de H o un grupo proyector de amino; Y es un grupo alcoxi que tiene entre 1 y 4 átomos de C, un grupo dialquilamino que tiene entre 2 y 8 átomos de C, un grupo imidazolilo, un grupo ftalimidilo, grupo succinimidilo o grupo sulfonilo; y m es 1 o 2. Reivindicacion 12: Un compuesto de formula (3) o una sal del mismo, en la que: A es un grupo alquileno C1-4, estando dicho grupo alquileno no sustituido o sustituido con 1 a 4 sustituyentes seleccionados independientemente entre el grupo constituido por un átomo de halogeno, un grupo alquilo C1-4, un grupo hidroxi-alquilo C1-4 y un grupo alcoxi-alquilo C2-6, en el que 2 sustituyentes no halogeno cualquiera se pueden tomar juntos con los átomos de C a los que están unidos para formar un anillo de 3 a 6 miembros que opcionalmente contiene al menos un heteroátomo seleccionado entre N, O y S; R2 es un átomo de H, un grupo hidroxi o un átomo de halogeno; R4 es un grupo hidroxi o un grupo protector de carboxi; R6 es un átomo de H o un grupo protector de amino; y m es 1 o 2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004177488A JP4129445B2 (ja) | 2004-06-15 | 2004-06-15 | ベンズイミダゾロンカルボン酸誘導体 |
| US60700804P | 2004-09-02 | 2004-09-02 | |
| US60703504P | 2004-09-02 | 2004-09-02 | |
| US60704804P | 2004-09-02 | 2004-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049353A1 true AR049353A1 (es) | 2006-07-19 |
Family
ID=35414645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102433A AR049353A1 (es) | 2004-06-15 | 2005-06-14 | Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7595329B2 (es) |
| EP (1) | EP1758891A2 (es) |
| KR (1) | KR100875558B1 (es) |
| AR (1) | AR049353A1 (es) |
| AU (1) | AU2005254800B2 (es) |
| BR (1) | BRPI0512046A (es) |
| CA (1) | CA2569654C (es) |
| CR (1) | CR8756A (es) |
| EA (3) | EA200801608A1 (es) |
| EC (1) | ECSP067079A (es) |
| GE (1) | GEP20094638B (es) |
| GT (1) | GT200500156A (es) |
| IL (1) | IL179612A (es) |
| MA (1) | MA28667B1 (es) |
| MX (1) | MXPA06014486A (es) |
| NL (1) | NL1029250C2 (es) |
| NO (1) | NO20065160L (es) |
| PA (1) | PA8636901A1 (es) |
| PE (1) | PE20060298A1 (es) |
| SV (1) | SV2008002145A (es) |
| TW (1) | TWI298635B (es) |
| UY (1) | UY28961A1 (es) |
| WO (1) | WO2005123718A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU714980B2 (en) | 1996-07-24 | 2000-01-13 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| CA2569654C (en) * | 2004-06-15 | 2010-12-21 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| ES2332808T3 (es) * | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
| US7396933B2 (en) * | 2004-11-05 | 2008-07-08 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| MX2007007818A (es) * | 2004-12-22 | 2007-09-11 | Theravance Inc | Compuestos de indazol-carboxamida. |
| ES2366375T3 (es) | 2005-02-22 | 2011-10-19 | Pfizer, Inc. | Derivados de oxiindol, como agonistas del receptor 5-ht4. |
| CN101163701A (zh) * | 2005-03-02 | 2008-04-16 | 施万制药 | 作为5-ht4受体激动剂的喹啉酮化合物 |
| JP2008533121A (ja) * | 2005-03-15 | 2008-08-21 | ファイザー株式会社 | Ｃｂ２受容体リガンドとしてのベンズイミダゾロン誘導体 |
| CA2611153A1 (en) * | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine t-type calcium channel antagonists |
| JP2009500340A (ja) * | 2005-06-29 | 2009-01-08 | メルク エンド カムパニー インコーポレーテッド | ４−フルオロ−ピペリジンｔ型カルシウムチャネルアンタゴニスト |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP2682130A1 (en) * | 2006-01-24 | 2014-01-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| US20090298811A1 (en) * | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
| US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102753527B (zh) | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| EP2533780B1 (en) | 2010-02-12 | 2017-08-23 | AskAt Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH566987A5 (es) | 1972-04-21 | 1975-09-30 | Ciba Geigy Ag | |
| US3945953A (en) | 1972-04-21 | 1976-03-23 | Ciba-Geigy Corporation | ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use |
| JPS5965073A (ja) | 1982-10-05 | 1984-04-13 | Kowa Co | インド−ル誘導体 |
| DE3336024A1 (de) | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
| US5193547A (en) * | 1984-07-16 | 1993-03-16 | Evans Ii George D | Universal connector means for transducer/monitor systems |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| US5552408A (en) | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
| JP2643274B2 (ja) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | イミダゾ〔１，２−ａ〕ピリジン誘導体 |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| WO1991000858A1 (en) | 1989-07-07 | 1991-01-24 | Schering Corporation | Pharmaceutically active compounds |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9009389D0 (en) | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| EP0566609A1 (en) | 1991-01-09 | 1993-10-27 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
| US5196547A (en) | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| US5219850A (en) | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5137893A (en) | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5955470A (en) | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| EP0522914A1 (fr) | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
| IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5521193A (en) | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
| FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
| MX9305947A (es) | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
| GB9221468D0 (en) | 1992-10-13 | 1992-11-25 | Smithkline Beecham Plc | Pharmaceuticals |
| AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
| TW251287B (es) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| US5534521A (en) | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
| CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| US5864039A (en) | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| AU3192295A (en) | 1994-08-11 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition containing the same |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| NZ321626A (en) | 1995-11-09 | 1998-10-28 | Synthelabo | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands |
| US6066738A (en) | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| JPH10203987A (ja) | 1997-01-28 | 1998-08-04 | Dainippon Pharmaceut Co Ltd | （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤 |
| FR2762316B1 (fr) | 1997-04-18 | 1999-12-17 | Sanofi Synthelabo | Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6207697B1 (en) | 1997-09-09 | 2001-03-27 | Dupont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa |
| US6069152A (en) | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| WO1999050264A1 (en) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Quinazoline derivatives |
| RU2230740C2 (ru) | 1998-03-31 | 2004-06-20 | Акадиа Фармасьютикалз, Инк. | Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| JP2002528533A (ja) | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | 酵素ｉｍｐｄｈの新規なインヒビター |
| US6420410B1 (en) | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| JP2003518107A (ja) | 1999-12-20 | 2003-06-03 | ニューロメド テクノロジーズ， インコーポレイテッド | 部分飽和カルシウムチャネルブロッカー |
| FR2805815B1 (fr) | 2000-03-01 | 2002-05-17 | Sanofi Synthelabo | Derives de polyfluoroalkylimidazole, leur preparation et leur application en therapeutique |
| BR0113590A (pt) * | 2000-08-31 | 2003-07-22 | Hoffmann La Roche | 7-oxo-piridopirimidinas |
| US20020128232A1 (en) | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
| AU2002239508B9 (en) | 2000-12-07 | 2005-09-08 | Gilead Palo Alto, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2433174A1 (en) | 2000-12-28 | 2002-07-11 | Mochida Pharmaceutical Co., Ltd. | Cholesterol biosynthesis inhibitor containing tricyclic compound having spiro union as effective component |
| US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
| MXPA03000145A (es) | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| CA2499494A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| EP1637521B1 (en) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
| GEP20084527B (en) | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| CA2569654C (en) | 2004-06-15 | 2010-12-21 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
-
2005
- 2005-06-01 CA CA2569654A patent/CA2569654C/en not_active Expired - Fee Related
- 2005-06-01 MX MXPA06014486A patent/MXPA06014486A/es active IP Right Grant
- 2005-06-01 EA EA200801608A patent/EA200801608A1/xx unknown
- 2005-06-01 GE GEAP20059755A patent/GEP20094638B/en unknown
- 2005-06-01 BR BRPI0512046-2A patent/BRPI0512046A/pt not_active IP Right Cessation
- 2005-06-01 WO PCT/IB2005/001825 patent/WO2005123718A2/en not_active Ceased
- 2005-06-01 AU AU2005254800A patent/AU2005254800B2/en not_active Ceased
- 2005-06-01 EP EP05750293A patent/EP1758891A2/en not_active Withdrawn
- 2005-06-01 KR KR1020067026378A patent/KR100875558B1/ko not_active Expired - Fee Related
- 2005-06-01 EA EA200602122A patent/EA010891B9/ru not_active IP Right Cessation
- 2005-06-01 EA EA200801607A patent/EA200801607A1/xx unknown
- 2005-06-13 PE PE2005000671A patent/PE20060298A1/es not_active Application Discontinuation
- 2005-06-14 US US11/153,757 patent/US7595329B2/en not_active Expired - Fee Related
- 2005-06-14 TW TW094119692A patent/TWI298635B/zh not_active IP Right Cessation
- 2005-06-14 NL NL1029250A patent/NL1029250C2/nl not_active IP Right Cessation
- 2005-06-14 AR ARP050102433A patent/AR049353A1/es not_active Application Discontinuation
- 2005-06-14 US US11/153,775 patent/US7705020B2/en not_active Expired - Fee Related
- 2005-06-14 UY UY28961A patent/UY28961A1/es not_active Application Discontinuation
- 2005-06-15 PA PA20058636901A patent/PA8636901A1/es unknown
- 2005-06-15 SV SV2005002145A patent/SV2008002145A/es unknown
- 2005-06-15 GT GT200500156A patent/GT200500156A/es unknown
-
2006
- 2006-11-09 NO NO20065160A patent/NO20065160L/no not_active Application Discontinuation
- 2006-11-20 CR CR8756A patent/CR8756A/es unknown
- 2006-11-27 IL IL179612A patent/IL179612A/en not_active IP Right Cessation
- 2006-12-13 EC EC2006007079A patent/ECSP067079A/es unknown
- 2006-12-15 MA MA29536A patent/MA28667B1/fr unknown
-
2008
- 2008-01-09 US US11/971,265 patent/US20080108660A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049353A1 (es) | Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. | |
| KR101377790B1 (ko) | 인돌 화합물 및 이의 용도 | |
| AR053548A1 (es) | Derivados de oxiindol | |
| ES2916426T3 (es) | Formas sólidas de un inhibidor de la cápside del VIH | |
| CN109890808B (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| ES2705709T3 (es) | Compuestos de isoquinolina para el tratamiento del VIH | |
| ES2641833T3 (es) | Inhibidores bicíclicos de la acetil-CoA carboxilasa | |
| RU2448096C2 (ru) | Диарилгидантоины | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2737190C2 (ru) | Ингибиторы репликации вируса гриппа, способы их применения и использование | |
| AR045552A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| HUE035462T2 (en) | Bicyclic substituted uracil derivatives and their use | |
| BRPI0713253A2 (pt) | método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica | |
| UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
| AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
| AR071222A1 (es) | Compuestos heterociclicos espirocondensados | |
| JP2006504621A (ja) | Ｈｉｖプロテアーゼ阻害剤としてのカルバミン酸エステル | |
| KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
| CN106458916A (zh) | 受限制的三环磺酰胺 | |
| AR071592A1 (es) | Fenoxibenzamidas sustituidas | |
| JP2014522396A (ja) | 置換２−ベンジリデン−２Ｈ−ベンゾ［ｂ］［１，４］チアジン−３（４Ｈ）−オン、その誘導体及びその治療上の使用 | |
| JP2004529145A5 (es) | ||
| RU2403253C2 (ru) | Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а | |
| CA2615611A1 (en) | Indazole derivatives | |
| RU2010116779A (ru) | Производное амида индазолакриловой кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |